Physician profile
Scott Y Wu
NPI 1760426308
$19,947.99
in general payments reported to CMS, 2019-2025
41 companies · $5,584 in 2025
The $5,584 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,918 · 2020: $817 · 2021: $1,759 · 2022: $1,876 · 2023: $2,471 · 2024: $5,523 · 2025: $5,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,610 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,125 · Consulting Fee: $1,695 · Travel and Lodging: $77.00 · Education: $70.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,610.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,125.00 |
| Consulting Fee | $1,695.00 |
| Travel and Lodging | $77.00 |
| Education | $70.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $5,350.62 | 2024-2025 | Voquezna |
| Abbvie INC. | $4,617.18 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $3,620.53 | 2019-2025 | Eohilia, Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,409.92 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,254.34 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Merck Sharp & Dohme LLC | $535.09 | 2019-2024 | Dificid, Zinplava |
| Celgene Corporation | $321.21 | 2021-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $222.55 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $218.28 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $202.04 | 2021-2025 | |
| Boston Scientific Corporation | $192.42 | 2019-2024 | Watchman Access System |
| Aimmune Therapeutics, INC. | $181.65 | 2023-2025 | Zenpep |
| Ucb, INC. | $167.53 | 2019-2020 | |
| Ardelyx, INC. | $158.52 | 2022-2025 | Ibsrela |
| Janssen Pharmaceuticals, INC | $140.75 | 2019-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $123.52 | 2019 | |
| Mauna Kea Technologies, INC. | $115.24 | 2019 | |
| Lilly USA, LLC | $109.09 | 2023-2025 | Omvoh |
| Organon LLC | $102.99 | 2021-2025 | Renflexis, Hadlima |
| Pfizer INC. | $101.66 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.47 | 2023-2024 | Cyltezo |
| Medtronic USA, INC. | $71.94 | 2019 | |
| Braintree Laboratories, INC. | $67.56 | 2019-2024 | Sutab, Suflave |
| Amgen INC. | $62.15 | 2022-2023 | Avsola, Amjevita |
| Intercept Pharmaceuticals, INC. | $51.12 | 2019-2023 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $50.98 | 2020-2021 | |
| Genzyme Corporation | $48.80 | 2019-2022 | |
| Orphalan INC | $47.69 | 2024-2025 | Cuvrior |
| Ironwood Pharmaceuticals, INC | $44.98 | 2021-2024 | Linzess |
| Celltrion USA INC. | $36.14 | 2025 | Vegzelma |
| Ferring Pharmaceuticals INC. | $35.33 | 2021-2023 | Rebyota |
| Medtronic, INC. | $34.77 | 2022 | |
| Qol Medical, LLC | $33.24 | 2022-2025 | Sucraid |
| Amag Pharmaceuticals, INC. | $31.83 | 2021-2022 | |
| Sandoz INC. | $17.26 | 2024 | Hyrimoz |
| Ultragenyx Pharmaceutical INC. | $15.01 | 2021 | |
| Digestive Care, INC. | $14.26 | 2025 | Pertzye |
| Mallinckrodt Hospital Products INC. | $14.08 | 2025 | Terlivaz |
| W. L. Gore & Associates, INC. | $12.25 | 2020 | |
| Alfasigma USA, INC. | $12.00 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$19,987.16 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.